News & Updates

Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024. 

Diabetic patients with primary open-angle glaucoma (POAG) are at greater risk of developing diabetic retinopathy (DR), reveals a study, noting the need for screening and comprehensive management in glaucomatous patients with diabetes to reduce the risk of DR.

Adherence to a healthy dietary pattern, such as the Mediterranean diet (MedDiet), may reduce the risk of gestational diabetes mellitus (GDM) but appears to increase exposure to harmful chemicals, according to a Singapore study presented at ADA 2024.

In patients with type 1 diabetes (T1D) treated with SGLT2 inhibitors, such as dapagliflozin, the addition of pioglitazone helps to intensify the reduction in HbA1c and blocks the increase in plasma ketone driven by SGLT2 inhibitors, reports a study presented at ADA 2024. This enables long-term cardiovascular and renal outcome studies to be safely performed in T1D patients.

Depressive symptoms are likely to occur in middle-aged and older men with hypogonadism, but low-grade persistent depressive disorder (LG-PDD) is rare, according to a study.

In patients with type 2 diabetes (T2D), moderate-intensity statin in combination with ezetimibe results in greater reductions in low-density lipoprotein cholesterol (LDL-C) and better prevention of adverse outcomes when compared with high-intensity statin monotherapy, suggests a study.